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Individuals with sickle cell disease (SCD) and sickle cell trait (SCT) have many risk factors that could make them
more susceptible to COVID-19 critical illness and death compared to the general population. With a growing
body of literature in this field, a comprehensive review is needed. We reviewed 71 COVID-19-related studies
conducted in 15 countries and published between January 1, 2020, and October 15, 2021, including a combined
total of over 2000 patients with SCD and nearly 2000 patients with SCT. Adults with SCD typically have a mild to
moderate COVID-19 disease course, but also a 2- to 7-fold increased risk of COVID-19-related hospitalization and
a 1.2-fold increased risk of COVID-19-related death as compared to adults without SCD, but not compared to
controls with similar comorbidities and end-organ damage. There is some evidence that persons with SCT have
increased risk of COVID-19-related hospitalization and death although more studies with risk-stratification and
properly matched controls are needed to confirm these findings. While the literature suggests that most children
with SCD and COVID-19 have mild disease and low risk of death, some children with SCD, especially those with
SCD-related comorbidities, are more likely to be hospitalized and require escalated care than children without
SCD. However, children with SCD are less likely to experience COVID-19-related severe illness and death
compared to adults with or without SCD. SCD-directed therapies such as transfusion and hydroxyurea may be
associated with better COVID-19 outcomes, but prospective studies are needed for confirmation. While some
studies have reported favorable short-term outcomes for COVID-19 patients with SCD and SCT, the long-term
effects of SARS-CoV-2 infection are unknown and may affect individuals with SCD and SCT differently from
the general population. Important focus areas for future research should include multi-center studies with larger
sample sizes, assessment of hemoglobin genotype and SCD-modifying therapies on COVID-19 outcomes, inclu
sion of case-matched controls that account for the unique sample characteristics of SCD and SCT populations, and
longitudinal assessment of post-COVID-19 symptoms.

1. Introduction
Coronavirus disease 2019 (COVID-19) [1–3] is an infectious disease
caused by a newly discovered coronavirus (SARS-CoV-2), which has
impacted millions of people around the world and caused unprece
dented challenges to healthcare systems. Severe COVID-19 clinical
manifestations include acute respiratory distress syndrome (ARDS),

systemic inflammation, sepsis, multi-organ failure, and death, among
others [1–3]. Survivors of SARS-CoV-2 infection may experience
lingering symptoms and long-term health problems [4].
Sickle cell disease (SCD) is an inherited red blood cell disorder
caused by a single amino acid genetic mutation in the beta-chain of the
human hemoglobin protein [5,6]. Patients with SCD experience chronic
hemolytic anemia, recurrent vascular occlusion, insidious vital organ
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deterioration, early mortality, and poor quality of life [5,6]. Repeated
vaso-occlusive events may result in functional asplenia and immune
deficiency in early childhood leading to life-long increased susceptibility
to serious bacterial infections. Acute and chronic pain and other serious
health conditions such as acute chest syndrome (ACS) and stroke [7] are
also common in patients with SCD. SCD predominantly affects Black
individuals. In the United States, there are about 100,000 people living
with SCD, with 1 in 500 African Americans being affected by the disease
[8].
Individuals with sickle cell trait (SCT) may also exhibit adverse
health effects including exertional rhabdomyolysis, pulmonary embo
lism, splenic infarction, and renal damage [9,10]. Approximately 300
million people worldwide and 1 to 3 million in the United States (8% to
10% of African Americans) live with SCT [10–12].
There is conflicting evidence whether patients with SCD or SCT
experience more severe COVID-19 disease, with higher morbidity and
mortality rate than the general population. SCD pathophysiology results
in chronic anemia, endothelial dysfunction, chronic inflammation,
immunocompromised status, and hypercoagulability, all of which have
been identified as risk factors for worse COVID-19 outcomes [13–16].
Individuals with SCT do have a hypercoagulable state and sickling
pathophysiology in hypoxic environments such as the renal medulla and
could potentially be at higher risk for severe COVID-19 outcomes as
well.
In this paper, we present a comprehensive review of the literature of

COVID-19 patients with SCD and SCT and highlight both the conclusions
and limitations drawn from the literature, which can serve as important
considerations for future research. We also discuss clinical course, hos
pitalization trends, mortality, risk factors, and SCD-disease modifying
therapies among children and adults (separately) with SCD and SCT
(separately) who have COVID-19 disease.
2. Methods
A structured literature search was conducted using PubMed to
include all relevant articles that were dated between January 1, 2020,
and October 15, 2021. The selection process is detailed in Fig. 1. The
review was conducted according to the PRISMA 2020 27-item checklist
[17]. Titles and abstracts were searched to identify the literature related
to COVID-19 and SCD/SCT. The primary search term used was ‘COVID19 sickle cell’ which yielded 157 articles. Additional references were
retrieved from the bibliographies of the articles identified by the pri
mary search. Of the original 164 records screened, 50 were excluded
because they were unrelated to SCD and COVID-19, and 43 were
excluded because they were not available in English or did not include
original clinical data on SCD or SCT patients with positive or suspected
COVID-19. After this filter, a total of 71 publications were retained and
systematically reviewed.

Fig. 1. PRISMA flow chart used to identify original research articles on COVID-19 patients with sickle cell disease or sickle cell trait.
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2.1. Statistical analysis

COVID-19 could be explained by the short life expectancy of SCD pa
tients (43 years in 2017 [18]) relative to the general population (79
years in 2017 [19]). Despite young age, SCD patients had substantial
comorbidities (i.e., hypertension, asthma/COPD, and chronic kidney
disease), consistent with end-organ damage from SCD [20,21].
At hospital presentation, oxygen saturation was 95%, body temper
ature was 101.6F, and BMI was 28. Laboratory values were above
normal range for lactate dehydrogenase, bilirubin, white blood cell
count, C-reactive protein, and D-dimer; below normal range for hemo
globin; and within normal range for lymphocyte count. These altered
laboratory values are consistent with SCD-related manifestations of red
blood cell dysfunction [6,22]. Elevated lactate dehydrogenase and Ddimer could be suggestive of more severe COVID-19 disease [23] but
could also result from intravascular hemolysis, ischemia-reperfusion
damage and tissue necrosis associated with SCD and could be further
elevated during acute vaso-occlusive crisis [24].

In this systematic review, we used descriptive statistics to summarize
aggregated demographic and clinical data of SCD and SCT patients with
SARS-CoV-2 infection based on the literature included in this review
(Table 1), including median and interquartile range for age, vitals, and
laboratory values. The categorical variables female sex, hemoglobin
genotype, and comorbidities were described as n (% of the sample). The
overall mortality rate for SCD/non-SCD was calculated as the total
number of COVID-19-related deaths among SCD/non-SCD patients re
ported in observational cohort studies divided by the total number of
SCD/non-SCD patients with COVID-19 reported by the same studies.
Relative risk of death for SCD was estimated as the absolute risk in the
SCD group divided by the absolute risk in the non-SCD group.
3. Patients with COVID-19 and sickle cell disease
Of the 71 reports identified in this review, 67 studies (25 observa
tional cohort studies and 42 case studies) reported on SCD patients
describing a combined total of 2290 patients with SCD and COVID-19. A
detailed summary of study parameters and main study findings are
presented in Table 2 (observational studies) and Table 3 (case studies).

3.2. Clinical course
Adult SCD patients typically experience mild to moderate COVID-19related symptoms [25–32], which is characterized by few respiratory
symptoms and not requiring intensive care unit (ICU) admission. Large
US registry studies found that approximately 80% of adult SCD patients
experience mild to moderate symptoms (or no symptoms at all) [29,30]
and that the type of COVID-19-related symptoms, including cough/fever
or more severe symptoms such as respiratory failure, were not different
from patients without SCD [33]. However, SCD-related comorbidities, in
particular acute pain has been found highly prevalent during COVID-19,
and history of pain was associated with increased risk of hospitalization
[29].
A few smaller cohort studies observed more severe COVID-19 disease
course among adult SCD patients [34–37]. Severe disease course is
typically characterized by patients needing escalated care and pro
longed hospitalization due to severe COVID-19 symptoms (e.g., hypoxia,
pneumonia, prolonged fever, multisystem inflammation) or severe SCDrelated complications (e.g., ACS, severe pain crisis), or both. One study
observed increased hospitalization, mild to moderate pneumonia, and
intubation among SCD patients as compared to age-matched healthcare
professionals [37]. Another study identified older patients, pre-existing
conditions, and end-organ damage as high risk factors for severe COVID19 disease course and poor outcome [36].

3.1. Sample characteristics
There were 2290 persons with SCD and SARS-CoV-2 infection
analyzed by all studies combined and included in this review (Table 1).
The SCD cohort had a median age of 25 years (interquartile range =
17–39 years), was 56% female, and 62% had Hb-SS hemoglobin geno
type (Table 1). The relatively young age of patients with SCD and
Table 1
Sample characteristics of all COVID-19 patients with sickle cell disease (SCD) or
sickle cell trait (SCT) based on aggregated data from the literature included in
this review.

Demographics
Age in years, median
(IQR)
Female sex, n (%)
HbSS genotype, n (%)
Comorbidities, n (%)
Cardiovascular disease
Chronic kidney disease
Asthma or COPD
Diabetes
Heart failure
Hypertension
Liver disease
Stroke
Vitals, median (IQR)
Oxygen saturation (%)
Body temperature (F)
Body mass index (kg/
m2 )
Laboratory Values,
median (IQR)
Lactate dehydrogenase
(U/L)
Lymphocytes (x109/L)
Total bilirubin (mg/dL)
White blood cell count
(x109/L)
Hemoglobin (g/dL)
C-reactive protein (mg/
dL)
D-dimer (μg/mL)

SCD
n = 2290

n

SCT
n = 1937

n

25 (17–39)

140

54 (40–61)

24

1041 (56)
171 (62)

1858
278
1025

319 (54)
n/a

591
n/a
563

28 (3)
107 (10)
113 (11)
50 (5)
46 (5)
149 (15)
31 (3)
100 (10)
95 (88–97)
101.6
(100.4–102.3)
28 (25–34)

70
44

38 (7)
67 (12)
170 (30)
137 (23)
46 (8)
237 (42)
34 (6)
15 (3)

30

96 (91–98)
100.3
(98.7–101.6)
32 (27–35)

18

732 (495–917)

47

392 (292–576)

10

2.3 (1.2–4.4)
2.7 (0.9–4.3)
13 (8.3–18.2)

70
36
75

0.9 (0.6–1.4)
0.5 (0.4–1.1)
8.8 (5–13.3)

13
11
16

8.0 (6.7–9.6)
6.3 (0.9–18.7)

100
72

11.4 (9.8–13)
9.9 (2.2–20.5)

16
10

3.3 (0.8–7.7)

50

1.3 (2.7–21.5)

8

3.3. Hospitalization trends
There is strong evidence that patients with SCD have an increased
risk of COVID-19-related hospital admissions. Large cohort studies in the
UK and US have reported a 2- to 7-fold increased risk of COVID-19related hospital admission for patients with SCD relative to the gen
eral population [33,38,39]. Most observational studies reported hospi
talization rates of greater than or equal to 40% among patients with SCD
and SARS-CoV-2 infection [26,28,30,32,35,36,33,39,40], which
remained increased after age, gender, and race adjustment when
compared to the general population [33,38,39]. The hospitalization rate
of individuals with SARS-CoV-2 infection in the general population is
markedly lower. For example, peak hospitalization for the US popula
tion was 20.5% (first week of January 2021; https://covid.cdc.gov/covi
d-data-tracker/) and 19.2% in Black patients without SCD in a large US
registry study [33]. Case studies show even higher hospitalization
trends, although this may be in part due to patient selection bias. Of the
9 case studies that reported both hospitalized and non-hospitalized pa
tients, the COVID-19-related hospitalization rate for persons with SCD
was 72% (44/61) [41–45].
There could be several explanations for the high hospitalization rate
observed among patients with SCD. We hypothesize that the high
baseline hospital admission and readmission rate for patients with SCD,
independent of COVID-19, may have been contributing factors, in

16
15

Abbreviations: COPD, chronic obstructive pulmonary disease; IQR, interquartile
range.
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Table 2
Observational cohort studies of patients with SCD and COVID-19. Authors listed in alphabetical order.
Authors

Country

Sample
size
n (M/F)

Age
(years)

Hb
genotype
(n)

SCD
therapy
(n)

Control group

AbdulRahman
et al. [25]

Bahrain

38 (11/
27)

36

n/a

n/a

COVID-19 w/
o SCD

Alhumaid et al.
[34]1

Saudi
Arabia

31 (n/a)

n/a

n/a

n/a

None

Alkindi et al.
[26]

Oman

50 (27/
23)

31

HbSS (10),
HbSβ0 (29),
Unknown
(11)

BT (26)

SCD w/o
COVID-19

Al Yazidi et al.
[64]1

Oman

7 (n/a)

n/a

n/a

BT (2)

None

Arlet et al. [27]

France

83 (38/
45)

30

HbSS or
HbSβ0 (71),
HbSC (8),
HbSβ+ (4)

HU (38),
BT (31)

COVID-19 w/
o SCD

Balanchivadze
et al. [28]

USA

6 (3/3)

38

HbSS (4),
HbSC (1),
HbSβ+ (1)

BT (2)

None

Boğa et al. [37]

Turkey

39 (17/
22)

35

HbSS (23),
HbSβ+
(15), HbSE
(1)

HU (25),
BT (8)

COVID-19 w/
o SCD

Brousse et al.
[70]

France

39 (n/a)

12

HbSS (35),
HbSC (3),
HbSβ+ (1)

HU (25)

SCD w/o
COVID-19

Clift et al. [38]

UK

287 (n/
a)

n/a

n/a

n/a

COVID-19 w/
o SCD

De Sanctis et al.
[35]1

Oman

3 (1/2)

27

n/a

HU (3),
BT (1)

None

Fisler et al.
[90]1
Gampel et al.
[65]1

USA

2 (n/a)

n/a

n/a

n/a

None

USA

1 (1/0)

12

HbSC

n/a

None

Hippisley-Cox
et al. [52]1

UK

n/a

n/a

n/a

n/a

COVID-19 w/
o SCD

Hoogenboom
et al. [39]

USA

53 (28/
25)

30

HbSS (39),
HbSC (11),
HbSβ (3)

n/a

Matched and
unmatched
COVID-19
pts. w/o SCD

Main findings

SCD is not a risk factor for
worse COVID-19 outcomes
in hospitalized pts.
compared to non-SCD pts.
hospitalized with COVID-19.
14 of 31 SCD pts. with
COVID-19 required
admission to the ICU.
Although COVID-19 may
trigger VOC onset, it does
not increase mortality
compared to non-COVID-19
pts. with VOC.
SCD is the most common
comorbidity associated with
COVID-19 pediatric
admission. Children with
SCD and COVID-19 are more
susceptible to complications.
SCD pts. did not have
increased risk of morbidity
or mortality; VOC
complicates infection; Older
pts. are at higher risk and
should be monitored
carefully.
SCD pts. generally had mild
disease course with lower
chances of intubation, ICU
admission, and death.
SCD pts. had more severe
disease course (pneumonia,
hosp., intubation) than nonSCD healthcare
professionals.
Among seropositive
patients, none had displayed
symptoms except one who
was hospitalized for mild
vaso-occlusive symptoms
with a favorable outcome.
SCD pts. had 4-fold and 2.6fold increased risk of
hospitalization and death
due to COVID-19,
respectively.
SCD and other comorbidities
can aggravate COVID-19
severity despite favorable
outcome; Two SCD pts. had
worsening anemia;
Respiratory complications
rapidly improved after red
blood cell exchange BT in
one patient.
Two SCD pts. were admitted
to ICU for ACS.
SCD pt. with h/o prior
pulmonary and cardiac
complications died of
COVID-19 disease.
SCD vaccinated pts. had 7.7fold increased risk of COVID19 mortality.
SCD pts. were more likely to
visit the ED and be
hospitalized than the general
population. Mortality,
severe disease, and other
outcomes in SCD pts. was
not different from controls.

SCD

Non-SCD

Hosp.
rate
n (%)

Mort.
rate
n (%)

Hosp.
rate
n (%)

Mort.
rate
n (%)

n/a

1
(2.6)

n/a

58 (3.3)

n/a

n/a

n/a

n/a

34
(68)

2 (4)

47
(70)2

3 (6)

n/a

0 (0)

n/a

n/a

n/a

2 (2)

n/a

2891
(7)

4 (67)

0 (0)

n/a

n/a

10
(26)

2 (5)

9 (7)

0 (0)

1 (2.6)

0 (0)

n/a

n/a

40
(14)

10
(3.5)

23,561
(4.4)

19,008
(3.5)

2 (67)

0 (0)

n/a

n/a

n/a

n/a

n/a

n/a

n/a

1
(100)

n/a

n/a

n/a

n/a

n/a

n/a

39
(74)

3 (8)3

n/a

5 (6)3

(continued on next page)
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Table 2 (continued )
Authors

Country

Sample
size
n (M/F)

Age
(years)

Hb
genotype
(n)

SCD
therapy
(n)

Control group

Kamdar et al.
[40]

USA

30 (n/a)

n/a

n/a

HU (19),
BT (3)

None

Konté et al.
[100]

Netherlands

5 (n/a)

n/a

n/a

n/a

None

Minniti et al.
[36]

USA

66 (30/
36)

34

HbSS or
HbSβ0 (47),
HbSC (14),
HbSβ+ (5)

HU (28),
BT (30)

None

Mucalo et al.
[29]4

USA

364
(187/
176)

11

HU
(203),
BT (39)

None

Mucalo et al.
[29]5

USA

386
(159/
220)

31

HU
(191),
BT (53)

None

Nathan et al.
[66]1
Oualha et al.
[101]1

France

3 (− /2)

17

HbSS or
HbSβ0
(263),
HbSC or
HbSβ+ (98)
HbSS or
HbSβ0
(261),
HbSC or
HbSβ+
(113)
n/a

BT (2)

None

France

4 (n/a)

n/a

n/a

n/a

None

Panepinto et al.
[30]

USA

178
(75/
101)

29

BT (68)

None

Ramachandran
et al. [31]
Singh et al. [
[33]]

USA

9 (5/4)

28

USA

312
(117/
195)

31

HbSS or
HbSβ0
(135),
HbSC or
HbSβ+
(42),
Unknown
(1)
HbSS (8),
HbSC (1)
n/a

HU, (6)
BT (6)
n/a

COVID-19 w/
o SCD
Matched
COVID-19
pts. w/o SCD

Telfer et al. [32]

UK

166
(71/95)

n/a

HbSS or
HbSβ0
(129);
HbSC,
HbSβ+, or
HbSE (37)

BT (60)

None

Waghmere et al.
[94]

India

7 (0/7)

28

HbSS (6),
HbSβ (1)

n/a

Pregnant
COVID-19 w/
o SCD

Main findings

SCD

Non-SCD

Hosp.
rate
n (%)

Mort.
rate
n (%)

Hosp.
rate
n (%)

Mort.
rate
n (%)

SCD pts. had more ED visits
and hospitalization than
other hematological pts.
with COVID-19.
Low incidence of COVID-19
in SCD pts. presenting with
VOC, suggesting that
COVID-19 is not a major
provoking factor for VOC.
SCD pts. over 50yo with
preexisting conditions with
elevated creatinine, LDH,
and D-dimer are at higher
risk of death regardless of
genotype or sex. All deaths
occurred in pts. not on HU.
SCD children with h/o pain,
renal, and heart/lung
comorbidities are at higher
risk of worse COVID-19
outcomes.
SCD Adults with h/o pain are
at higher risk of worse
COVID-19 outcomes.

14
(47)

0 (0)

n/a

n/a

n/a

n/a

n/a

n/a

50
(76)

7
(11)3

n/a

n/a

146
(40.1)

1
(0.3)

n/a

n/a

231
(59.8)

18
(4.7)

n/a

n/a

Two SCD pts. developed ACS
and required ICU and NIV.
All SCD pts. received BT for
respiratory deterioration in
ICU.
SCD pts. have a high risk for
severe disease course and
high case-fatality rate in
comparison to the US
population, and non-SCD
pts. of the same age showed
lower mortality.

n/a

0 (0)

n/a

n/a

n/a

0 (0)

n/a

n/a

122
(68.5)

13
(7.3)

n/a

n/a

SCD pts. had relatively mild
disease course.
Black SCD pts. are more
likely to be hospitalized and
develop pneumonia and pain
than Black pts. w/o SCD but
do not differ in mortality.
Significant number of
hemoglobinopathy pts. in
the UK developed COVID19; SCD pts. in the age
groups 18–49 and 50–79
have an increased risk of
COVID-19 related death.
Pregnant women with SCD
have increased risk of
pregnancy complications in
comparison to non-SCD
pregnant women.

n/a

0 (0)

n/a

3 (5.6)

129
(41.3)

10
(3.2)

60
(19.2)

10 (3.2)

128
(77)

11
(6.6)

n/a

n/a

n/a

0 (0)3

n/a

11
(0.7)3

Abbreviations: ACS, acute chest syndrome; AKI, acute kidney injury; ALI, acute liver injury; BT, blood transfusion; CKD, chronic kidney disease; DBP, diastolic blood
pressure; ED, emergency department; h/o, history of; Hosp., hospitalization; HTN, hypertension; HU, hydroxyurea; ICU, intensive care unit; IMV, invasive mechanical
ventilation; LOS, length of stay; n/a, not available, not applicable, unknown, or not specified; NIV, non-invasive ventilation; pts., patients; SCD, sickle cell disease; SCT,
sickle cell trait; VOC, vaso-occlusive crisis; w/o, without.
1
Focus of study was not SCD.
2
50 total patients with a total of 67 VOC episodes, hospitalization rate is based on total episodes.
3
In-hospital.
4
Pediatric arm of the study.
5
Adult arm of the study.
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Table 3
Case reports of patients with SCD and COVID-19. Authors listed in alphabetical order.
Authors

Country

Sample
size
n (M/F)

Age
(years)

Hb genotype (n)

SCD
therapy
(n)

Main findings

Hosp.
rate
n (%)

Mortality
rate
n (%)

AbdulRahman
et al. [102]
Al-Hebshi et al.
[75]

Bahrain

6 (4/2)

31

HbSS (6)

HU (6)

n/a

0 (0)

Saudi
Arabia

2 (1/1)

13

HbSS (2)

HU (2)
BT (1)

n/a

0 (0)

Allison et al. [67]

USA

1 (1/0)

27

HbSC (1)

BT (1)

n/a

0 (0)

Al-Naami et al.
[41]
Al-Naami et al.
[103]
Al Sabahi et al.
[76]
Al Yazidi et al.
[104]

Saudi
Arabia
Saudi
Arabia
Oman

3 (2/1)

25

HbSS (3)

HU (1)

2 (67)

0 (0)

1 (1/0)

29

HbSS/Sβ0

HU (1)

n/a

0 (0)

5 (4/1)

5

0 (0)

7 (n/a)

n/a

HU (2)
BT (4)
BT (2)

4 (80)

Oman

HbSS/HbSβ+ (4/
1)
n/a

Infection rate, clinical course, and viral clearance of SCD
pts. were no different from pts. w/o SCD.
VOC and ACS complicated infection but were effectively
treated according to national guideline and standard
practice.
Early red blood cell exchange treatment may have helped
mitigate COVID-19 pneumonia and ACS.
Disease course was mild to moderate w/o complications
or death.
Pt presented asymptomatic with h/o sore throat and loose
motions; Uneventful recovery.
Variable disease courses. All cases recovered.

n/a

0 (0)

André et al. [77]

France

1 (0/1)

5

n/a

n/a

n/a

0 (0)

Anusim et al. [42]

USA

11 (4/7)

44

HbSS (5), HbSC
(4), HbSβ+ (1),
HbSα (1)

BT (5)

10 (91)

2 (18)

Appiah-Kubi et al.
[78]

USA

7 (2/5)

14

HbSS (6),
HbSC (1)

HU (4)
BT (1)

4 (57)

0 (0)

Argüello-Marina
et al. [105]

Spain

7 (n/a)

n/a

n/a

n/a

5 (71)

0 (0)

Azerad et al.
[106]

Belgium

3 (1/2)

30

HbSS (3)

HU (3)
BT (3)

n/a

0 (0)

Beerkens et al.
[54]
Chakravorty
et al. [43]
Chen-Goodspeed
et al. [44]

USA

1 (1/0)

21

HbSβ0 (1)

n/a

0 (0)

UK

10 (3/7)

37

HbSS (10/10)

7 (70)

1 (10)

USA

5 (3/2)

31

HbSS (4), HbSC
(1)

HU (1)
BT (1)
HU (2)
BT (6)
HU (3)
BT (2)

Most pts. had SCD-related symptoms, including ACS, VOC,
and splenic sequestration. Three required supplemental
oxygen.
ICU admission for rapid respiratory degradation after
initial phase with mild symptoms.
Pt presentations varied from mild to severe; Older age/
milder genotypes had worse outcomes; ACS and COVID19 pneumonia present similarly and should be
differentiated before treatment.
One ICU stay, no intubations. Favorable outcomes were
due to early diagnosis, use of antivirals, anti-inflammatory
agents, and anticoagulants.
Two ICU admissions, one patient required ventilation.
Variable medications and treatments used. Overall,
patients had short lengths of stay and no deaths.
SCD pts. showed mild clinical presentation of COVID-19,
which can be misleading; If BT is performed, always
consider risk of DHTR.
COVID-19 may have caused or exacerbated ACS.

3 (60)

0 (0)

Dagalakis et al.
[79]
De Luna et al.
[107]
Elia et al. [[56]]

USA

1 (1/0)

0.5

HbSC

n/a

n/a

0 (0)

France

1 (1/0)

45

HbSS

BT (1)

n/a

0 (0)

Brazil

3 (1/2)

11

HbSS (2), HbSC
(1)

HU (2)

n/a

0 (0)

Ershler et al.
[108]
Espanol et al. [80]

USA

1 (0/1)

39

HbSS

BT (1)

n/a

0 (0)

USA

1 (0/1)

8

HbSS

HU (1)
BT (1)

n/a

0 (0)

Fronza et al.
[109]
Hardy et al. [110]

Italy

1 (0/1)

44

n/a

BT (1)

n/a

0 (0)

Ghana

3 (0/3)

28

BT (2)

n/a

0 (0)

Heilbronner et al.
[81]

France

4 (1/3)

15

HbSS (1),
HbSC (2)
HbSS (4)

n/a

0 (0)

Hussain et al.
[55]

USA

4 (2/2)

33

BT (1)

n/a

0 (0)

Jacob et al. [82]

USA

1 (1/0)

2

HbSS (2),
HbSC (1),
HbSβ+ (1)
HbSS

n/a

0 (0)

Justino et al.
[111]
Kasinathan et al.
[83]
Martone et al.
[84]

Brazil

1 (0/1)

35

HbSS

BT (1)

n/a

0 (0)

USA

1 (0/1)

20

HbSC

BT (1)

n/a

0 (0)

n/a

0 (0)

USA

1 (0/1)

19

0

HbSβ

HU (2)
BT (4)

HU (1)
BT (1)

BT (1)

All but one seemed to be experiencing a relatively mild
course despite significant comorbidities.
SCD pts. did not present typical COVID-19 symptoms but
rather more typical SCD symptoms, including VOC; SCD
pts. presenting with VOC should immediately be tested for
COVID-19.
Pediatric pt. presented with mild symptoms and remained
stable throughout hospitalization.
Severe pneumonia and severe ACS effectively treated with
hydroxychloroquine and tocilizumab.
SCD pts. showed better clinical evolution than predicted;
Pulmonary viral infections can trigger SCD symptoms and
need for hospitalization; COVID-19 symptoms are very
similar to ACS symptoms, which affects clinical decision.
Acute crisis and COVID-19 pneumonia effectively treated
with voxelotor in lieu of single BT.
Patient was successfully managed after developing severe
ACS secondary to COVID-19, complicated by cortical vein
thrombosis and multisystem inflammatory syndrome.
Patient recovered and was discharged after severe anemia
and acute lung failure.
One had severe COVID-19 pneumonia. Two had severe
SCD crisis. All had favorable outcomes.
All pts. presented with ACS and admitted to PICU. Pts
were effectively treated with erythrapheresis, NIV, and
typical supportive treatment.
All four pts. initially presented to the ED for typical VOC;
the clinical course of their COVID-19 infection was rather
mild.
Pediatric pt. with severe anemia, splenic sequestration
crisis and COVID-19; Pt greatly improved following BT.
Mild clinical course during hospitalization, with no
apparent morbidity related to COVID-19.
Despite previous h/o pulmonary disease and current
pregnancy, clinical course was very favorable.
SCD diagnosis was unknown at time of presentation.
Pulmonary embolism complicated condition.
PT developed ACS with fever, decreased hemoglobin, but
no hypoxemia, which was managed with BT and

(continued on next page)
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Table 3 (continued )
Authors

Country

Sample
size
n (M/F)

Age
(years)

Hb genotype (n)

SCD
therapy
(n)

HbSS or HbSβ0
(9),
HbSC (1)
HbSS (7),
HbS HPFH (1)

BT (5)

22

HbSS (2)

n/a

1 (0/1)

69

HbS HPFH

BT (1)

France

1 (0/1)

16

HbSS

Qatar

1 (1/0)

22

n/a

HU (1)
BT (1)
HU (1)
BT (1)

Okar et al. [69]

Qatar

1 (1/0)

48

n/a

HU (1)
BT (1)

Parodi et al. [86]

Italy

2 (1/1)

1.2

HbSS (2)

BT (2)

Quaresima et al.
[87]

Italy

1 (0/1)

18

HbSS

HU (1)
BT (1)

Roussel et al. [88]

France

1 (0/1)

6

HbSS

n/a

Sahu et al. [45]

USA

5 (2/3)

33

HbSS (2),
HbSC (2),
HbSβ (1)

HU (2)
BT (1)

Santos de Lima
et al. [114]

USA

1 (0/1)

43

n/a

BT (1)

Teulier et al.
[115]

France

1 (1/0)

33

HbSS

HU (1)
BT (1)

Walker et al. [89]

USA

1 (0/1)

10

HbSS

BT (1)

McCloskey et al.
[53]

UK

10 (8/2)

36

Morrone et al.
[73]

USA

8 (4/4)

16

Nur et al. [112]

Netherlands

2 (1/1)

Nguyen et al.
[113]

USA

Odiévre et al.
[85]
Okar et al. [68]

HU (3)
BT (3)

Main findings

antibiotics. Four weeks later, pt. was re-hospitalized with
post-COVID-19 encephalopathy, hyperammonemia,
hyperinflammation, and multi organ failure. Patient
recovered to neurologic baseline and normal liver
function.
Overall, the outcome of COVID-19 infection was favorable
for this cohort of SCD pts., unless there were significant
comorbidities.
SCD pts. not admitted and did not develop ACS were on
HU and had lower absolute monocyte counts compared to
those admitted and developed ACS.
COVID-19 might trigger VOC w/o typical flu-like
symptoms; ACS developed w/o typical COVID-19
pulmonary complications; SCD pts. presenting with VOC
should be tested for COVID-19.
SCD pt. requiring ICU admission w/ intubation and
mechanical ventilation quickly improved following RBC
exchange transfusion.
Tocilizumab proved to be an effective treatment for this
SCD patient with severe COVID-19 and ACS.
Due to similarities between ACS and COVID-19
pneumonia, SCD pts. should be closely monitored and
offered BT early in the clinical course to avoid clinical
deterioration.
Close monitoring of SCD pts. is essential despite favorable
outcomes due to acute complications; BT early in the
disease course is beneficial against hemolysis and VOC.
Severe SARS-CoV-2 infection revealed a hidden condition
of SCD.
Pt had ACS and abnormal chest CT but no resp. symptoms,
remained COVID-19 pos for a long time, and rare blood
type prohibited BT.
Cranial polyneuropathy was the first manifestation of
severe COVID-19 in a child and cranial nerve involvement
may indicate poor disease course.
None of the pts. required intensive care or mechanical
ventilation with only one patient had a new oxygen
requirement. SCD COVID-19 pts. need multidisciplinary
treatment of pneumonia, VOC, ACS, with supportive care
for favorable outcome.
Combination of COVID-19 and SCD may increase risk of
posterior reversible encephalopathy syndrome and
contribute to higher mortality.
SCD patient developed severe ARDS secondary to COVID19 and was successfully treated with anticoagulation and
extracorporeal membrane oxygenation; patient did not
develop pulmonary arterial hypertension, suggesting
different pathophysiology in SCD pts.
Patient developed COVID-19 and ACS requiring red blood
cell exchange and remdesivir treatment.

Hosp.
rate
n (%)

Mortality
rate
n (%)

n/a

1 (10)

5 (63)

0 (0)

n/a

0 (0)

n/a

0 (0)

n/a

0 (0)

n/a

0 (0)

n/a

0 (0)

n/a

0 (0)

n/a

0 (0)

n/a

0 (0)

4 (80)

0 (0)

n/a

0 (0)

n/a

0 (0)

n/a

0 (0)

Abbreviations: ACS, acute chest syndrome; ARDS, acute respiratory distress syndrome; BT, blood transfusion; CT, computed tomography; DHTR, delayed hemolytic
transfusion reaction; h/o, history of; Hosp., hospitalization; HPFH, hereditary persistent fetal hemoglobin; HU, hydroxyurea; ICU, intensive care unit; n/a, not
available, not applicable, unknown, or unspecified; pts., patients; NIV, non-invasive ventilation; PICU, pediatric intensive care unit; SCD, sickle cell disease; VOC, vasoocclusive crisis.

addition to perhaps COVID-19 triggering an acute vaso-occlusive crisis
requiring hospitalization, as well as overlap in SCD and COVID-19
symptoms (i.e., the clinical picture for both ACS and COVID-19 pneu
monia can be similar) [46–48]. From the aggregated data, 64% of SCD
patients presented with abnormal chest x-ray/computed tomography,
62% with pain crisis, and 42% with physician described diagnosis of
ACS. ACS is a leading cause of death in SCD patients [49,50] and it is
likely that SCD patients with COVID-19 were admitted to the hospitals as
a precaution.

the same cohort studies, there were 21,986 COVID-19-related fatalities
among 587,554 patients without SCD, which represents an overall
mortality rate of 3.7%. Based on this data from 7 different countries (i.e.,
Bahrain, France, India, Oman, Turkey, UK, and USA) SCD, relative to
non-SCD, is associated with an overall 1.2-fold increased risk of COVID19-related death among adult patients. In line with this observation, one
of the largest cohort studies with SCD patients to date [38], conducted in
the UK with a non-SCD comparison group and covariate-adjusted anal
ysis, showed that patients with SCD were 2.5-fold more likely to die from
COVID-19 than patients without SCD at any time during the study
(hazard ratio (HR) = 2.55, 95% CI = 1.36 to 4.75). Hazard ratio not only
considers the total number of events, such as in relative risk and odds
ratio estimates, but also the timing of each event [51]. Interestingly,
Hippisley-Cox et al. [52] analyzed vaccinated cohorts and reported a
substantially higher hazard ratio (HR = 7.73) for SCD patients than Clift

3.4. Risk of death
Among all observational cohort studies with adult patients included
in this review, there were 79 COVID-19-related fatalities among 1720
patients with SCD, which represents an overall mortality rate of 4.6%. In
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et al. 2021 [38] (HR = 2.55) who analyzed mostly unvaccinated people
in the same UK database. This may suggest that persons with SCD have a
suboptimal response to COVID-19 vaccination, which warrants further
investigation.
There are additional cohort studies that reported a higher risk of
COVID-19 related death associated with SCD [30,32,36,37], although
these studies lacked proper comparison groups. It is possible that
negative outcomes reported in some of these studies are associated with
other factors, such as access to care, pre-existing conditions, and other
risk factors unique to these study samples, rather than SCD itself [36].
Among case studies, nearly all studies reported favorable outcomes,
regardless of disease course. In 3 case studies, there were 4 deaths (all
adults) out of 121 individuals with SCD [42,53,43], which represents
3.3% mortality rate.
Interestingly, SCD cohort studies utilizing controls matched for preexisting conditions reported no significant differences in COVID-19related mortality rate between patients with or without SCD [39,33],
or between SCD patients with or without COVID-19 [26]. This implies
that SCD patients do not have different COVID-19-related mortality rate
as compared to non-SCD patients who have similar rates of comorbid
ities and end-organ damage. It further indicates that organ damage,
caused by SCD or another condition, is a risk factor for COVID-19 related
death.
Even though SCD is associated with increased risk of COVID-19
related death, it may not be as high as feared. While viral infections
can trigger SCD symptoms [50,54], favorable COVID-19 outcomes for
patients with SCD may in part be explained by the high hospitalization
rate for this population, which could have contributed to timely inter
vention for symptomatic patients and improved survival probability. It
is also possible that certain pathophysiological characteristics of SCD
provide protective effects from fatal COVID-19 disease [55]. In line with
this idea, some case studies reported that those with milder hemoglobin
genotype had worse outcomes [42,56], although this could also be
explained by a lack of hydroxyurea treatment associated with milder
genotypes, which may have contributed to unfavorable outcomes. It has
been recently demonstrated by proteomic analysis that neutrophils in
patients with SCD present an unexpected activation of the interferon-α
signaling pathway [57]. Interferons have been suggested as being a
potential treatment for COVID-19 due to its antiviral activities [58,59].
The notion that SCD has some protective effect against COVID-19 should
be further explored.
We conclude that based on the available empirical data in the liter
ature, adults with SCD have an increased risk of death and a different
temporal progression of death or survivorship curves following COVID19 diagnosis as compared to adults without SCD, unless compared to
controls with similar comorbidities and end-organ damage. The effects
of demographic, clinical, and socioeconomic variables on risk estimates
of critical illness and death are further discussed in section ‘3.5 Risk
factors.’ Of important note, although some studies have reported
favorable short-term outcomes among COVID-19 patients with SCD, the
long-term effects of SARS-CoV-2 infection are unknown. Patients with
COVID-19 and SCD may experience lingering symptoms and long-term
health problems that differ from the general population. Therefore,
long term follow-up studies of these individuals are warranted.
Furthermore, there is limited data on less severe and other types of
COVID-19-related outcomes among SCD patients. One cohort study re
ported that persons with SCD experience more COVID-19-related
pneumonia and pain than individuals without SCD [33].

different sickle genotypes, COVID-19 outcomes may vary between sickle
cell patients. Interestingly, various studies observed that genotypes
associated with milder SCD (i.e., HbSC, HbSE, HbSβ+) had no different
or worse outcomes than genotypes associated with more severe SCD (i.
e., HbSS, HbSβ0) [27,30,32,42,56]. We speculate that sickle cell anemiaspecific therapies or pathophysiology, such as activation of the inter
feron-α signaling pathway as discussed earlier in this work, may provide
a protective effect against COVID-19, but the reasons for this observa
tion are unknown and require further investigation. It is known, how
ever, that SCD symptoms could complicate the COVID-19 disease
course. For example, Mucalo et al. [29] reported that adults with a
history of pain are at higher risk of worse disease severity. Another
major concern unique to patients with SCD is pulmonary thrombosis,
which is prevalent in both SCD [62] and COVID-19 [63]. Therefore,
having both conditions could conceivably result in even higher risk of
severe disease. Persons with SCD would benefit from individual risk
assessment for poor COVID-19 outcomes although a history of SCD
complications does not necessarily lead to unfavorable outcomes. For
example, Anusim et al. [42] reported that prior sickle cell complications
such as avascular necrosis of the joints, hypersplenism requiring sple
nectomy, and cerebrovascular accident did not associated to the
outcome of patients with COVID-19.
3.6. SCD-modifying therapy
Several authors have speculated on the potential beneficial effects of
SCD directed therapies against COVID-19 disease. Simple or exchange
blood transfusion was the primary therapy reported by observational
cohort studies [26–32,35–37,40,64–66]. Among case studies, 47% of
SCD patients (60 out of 129 individuals) received regularly scheduled
chronic transfusion prior to COVID-19 diagnosis and/or received
transfusion during COVID-19 disease course. Several reports suggest
that early red blood cell exchange is successful in the treatment of severe
COVID-19 pneumonia [35,54,55,67], severe hemolysis and vasoocclusive crisis [68], and might prevent patients with SCD from expe
riencing further clinical deterioration [69] and intubation [67].
Hydroxyurea treatment is another common therapy for SCD
[27,29,31,35–37,40,70] and was received by 32% of SCD patients (41
out of 129 individuals) in case studies. The beneficial effects of hy
droxyurea treatment on SCD-related morbidity and mortality are well
known [71,72]. Minniti et al. [36] reported that all deaths occurred in
patients not on hydroxyurea or other SCD-modifying therapies. Morrone
et al. [73] reported that patients on hydroxyurea did not develop ACS.
Mucalo et al. [29] though found that hydroxyurea had no effect on
hospitalization or COVID-19 disease severity. Interestingly, of the 4 re
ported case-study deaths, 3 did not receive transfusion or hydroxyurea
treatment, and one patient did not have data on transfusion or hy
droxyurea treatment. Prospective studies are needed to further examine
the effects of SCD-modifying therapies on COVID-19 outcomes.
3.7. Pediatric patients with SCD
In the general population, children are less likely to experience se
vere COVID-19 outcomes as compared to adults [74], but only few
studies [29,70] have examined children with SCD and SARS-CoV-2
infection in sufficiently large cohorts from which valid inferences can
be drawn, as the vast majority of studies were case reports with less than
10 patients [56,65,66,73,75-89].
In one of the largest pediatric studies to date, Mucalo et al. [29]
analyzed 364 US children with SCD and SARS-CoV-2 infection (median
age 11 years, 72% Hb-SS/HbS-beta0 thalassemia, 56% on hydroxyurea
treatment) and found most children to be asymptomatic (25.5%) or to
experience mild to moderate symptoms (65.6%) although some had
more severe or critical symptoms (8.2%). Furthermore, the sample was
associated with 40% hospitalization rate, 5.8% ICU admission, 1.1%
ventilator use, and 1 death (0.3%). Risk factors for worse COVID-19

3.5. Risk factors
Observational cohort studies [27,29,32,36] and case reports [43,53]
suggest that advanced age, preexisting conditions, and male sex are risk
factors for unfavorable COVID-19 outcomes in patients with SCD,
similar to the reported risk factors in the general population [60,61].
Furthermore, because of marked differences in disease severity between
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outcomes were history of pain, and renal and heart/lung comorbidities.
No effects of hydroxyurea on hospitalization or COVID-19 severity were
observed. These findings were mostly in accordance with a smaller
French cohort study by Brousse and colleagues [70] who analyzed 39
children with SCD and SARS-CoV-2 infection (median age 12 years, 90%
Hb-SS, 64% on hydroxyurea treatment) and found that none had dis
played symptoms except one who was hospitalized for mild vasoocclusive symptoms with a favorable outcome. It was hypothesized
that activation of the type I Interferon (IFN-I) pathway may have
contributed to partial protection from SARS-CoV-2 severe illness and
death seen in their pediatric sample. Among the smaller pediatric studies
[56,65,66,73,75–89] that reported on a combined 42 children with SCD,
there was 1 (2.4%) patient with a history of prior pulmonary and cardiac
complications who died from COVID-19 disease.
While the literature suggests that most children with SCD who
become infected with SARS-CoV-2 have mild disease and low risk of
death, children with SCD, especially those with SCD-related comorbid
ities [29,65,66,90], are more likely to be hospitalized and require
escalated care than children without SCD of the same age [91]. How
ever, compared to adults with SCD [29] and adults without SCD [38],
children with SCD are less likely to experience COVID-19-related severe
illness and death. There was not sufficient data to review children with
SCT and COVID-19. Multicenter studies with larger sample size are

needed to confirm these preliminary findings.
4. Patients with COVID-19 and sickle cell trait
Table 4 summarizes the study parameters and main findings of 7
observational cohort studies [28,33,38,39,92–94] and 4 case studies
[75,90,95,96] reporting on a total of 1937 individuals with SCT and
COVID-19.
4.1. Sample characteristics
There were 1937 persons with SCT and SARS-CoV-2 infection
analyzed by all studies combined and included in this review (Table 1).
The SCT cohort had a median age of 54 years (interquartile range = 40
to 61 years) and was 54% female. A relatively large proportion of pa
tients had hypertension (42%), followed by asthma/COPD (30%) and
diabetes (23%), which may represent an age-related effect. Patients
presented with 96% oxygen saturation, 100.3F temperature, and a BMI
of 32. All laboratory values where within normal range, except for
lactate dehydrogenase, c-reactive protein, and D-dimer which were
above normal range possibly due to systemic inflammation and coagu
lation dysfunction associated with more severe COVID-19 [97,98]. Of
note, aggregated data, including laboratory values, should be

Table 4
Study characteristics and main findings of reports on individuals with SCT and COVID-19. Authors listed in alphabetical order.
Authors

Country

Study
type

Sample
size
n (M/F)

Age
(years)

Control group

Al-Hebshi et al.
[75]

Saudi
Arabia

Case
report

1 (0/1)

50

None

Balanchivadze
et al. [28]

USA

Case
report

18 (3/
15)

58

None

Clift et al. [38]

UK

Obs.

1346 (n/
a)

n/a

COVID-19 w/o
SCT

Hoogenboom
et al. [39]

USA

Obs.

62 (13/
49)

47

Merz et al. [93]

USA

Obs.

20 (11/
9)

66

Matched and
unmatched
COVID-19 w/o
SCT
COVID-19 w/o
SCT

Quaresima et al.
[87]

Italy

Obs.

2 (1/1)

51

None

Resurreccion
et al. [92]

UK

Case
report

14 (6/8)

64

COVID-19 w/o
SCT

Sheha et al. [95]

Egypt

Obs.

1 (0/1)

22

None

Singh et al. [
[33]]

USA

Case
report

37.7

Matched COVID19 pts. w/o SCT

Tafti et al. [96]

USA

Obs.

449
(237/
212)
1 (1/0)

33

None

Waghmere et al.
[94]

India

Obs.

24 (0/
24)

n/a

Pregnant COVID19 w/o SCT

Main findings

SCT

Non-SCT

Hosp.
rate
n (%)

Mort.
rate
n (%)

Hosp.
rate
n (%)

Mort.
rate
n (%)

No significant symptoms, except for
headache and fatigue prior to testing.
Normal labs and chest X-ray.
SCT pts. generally had mild disease
course with lower chances of intubation,
ICU admission, and death.
SCT pts. had 1.4-fold and 1.5-fold
increased risk of hospitalization and
death due to COVID-19, respectively.
SCT pts. did not differ from (un)matched
controls in laboratory values or
outcomes.

0 (0)

0 (0)

n/a

n/a

11
(61)

1 (6)

n/a

n/a

98
(7.3)

50
(3.7)

23,561
(4.4)

19,008
(3.5)

31
(50)

7
(23)1

n/a

20 (18)1

SCT did not impact respiratory, renal, or
circulatory complications or mortality in
COVID-19 pts. when compared to nonSCT pts.
Prolonged positivity for SARS-CoV-2, but
mostly asymptomatic to mild disease
course.
Black SCT pts. had similar infection rates,
but higher mortality compared to Black
pts. w/o SCT. Diabetes was a risk factor
for COVID-19 related death.
First case of SCD diagnosed due to
concurrent COVID-19.2
Black pts. with SCT did not differ in
COVID-19 disease course or outcomes
compared to Black pts. w/o SCT.
Pt developed rhabdomyolysis,
myonecrosis, and an abscess, all of which
were exacerbated by COVID-19 / SCT.
Pregnant women with SCT have
increased risk of pregnancy
complications in comparison to pregnant
women w/o SCT.

n/a

3
(15)1

n/a

19 (13)1

0 (0)

0 (0)

n/a

n/a

n/a

4 (29)

n/a

21 (13)

n/a

0 (0)

n/a

n/a

79
(18)

10
(2.2)

n/a

n/a

n/a

0 (0)

n/a

n/a

n/a

1
(4.2)1

n/a

11
(0.7)1

Abbreviations: ACS, acute chest syndrome; AKI, acute kidney injury; ALI, acute liver injury; ARDS, acute respiratory distress syndrome; CT, computed tomography; ED,
emergency department; Hosp., hospitalization; ICU, intensive care unit; IMV, invasive mechanical ventilation; LOS, length of stay; n/a, not available, not applicable,
unknown, or not specified; Mort., mortality; pts., patients; Obs., observational cohort study; SCD, sickle cell disease; SCT, sickle cell trait; w/o, without.
1
In-hospital.
2
Patient tested positive for SCT but was suspected SCD.
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interpreted with caution due to small sample sizes.

conditions, and male sex are risk factors for unfavorable COVID-19
outcomes in patients with SCD, similar to the reported risk factors in
the general population. There is some evidence that SCD-modifying
therapies such as transfusion and hydroxyurea may be associated with
better COVID-19 outcomes, but prospective studies are needed for
confirmation. There is some evidence that persons with SCT have
increased risk of COVID-19-related hospitalization and death although
more studies with risk-stratification and properly matched controls are
needed to confirm these findings.

4.2. Clinical course
Most studies [28,39,33,75,87,93] reported mild COVID-19 disease
course for individuals with SCT similar to individuals without SCT, and
only very few SCT patients required escalated care (i.e., intensive care,
intubation, need for mechanical ventilation) or developed severe disease
complications. However, pregnant women with SCT may experience
increased risk of pregnancy complications (e.g., gestational hyperten
sion, intrauterine growth restriction) and more COVID-19-related
symptoms in comparison to pregnant women without SCT [94].
Among case studies, only 2 patients with SCT reportedly had more se
vere disease course. In one case, the patient was not known to have SCT
prior to hospitalization for COVID-19 and may have had disease
phenotype masked by the transfusions [95]. The second SCT case had
rhabdomyolysis after significant exertion due to exercise [96]. Some
studies did not collect or analyze any clinical course data from its cohort
[38,92].

6. Future perspectives
Based on this review of the current literature, there are various
suggested future directions to move the field forward and improve our
understanding of COVID-19 outcomes among patients with SCD and
SCT. First, an important focus area for future studies should include
multi-center collaboration to generate larger cohorts, which will
generate more definite evidence related to COVID-19 outcomes among
patients with SCD/SCT. Currently, two-thirds of published COVID-19
studies with SCD/SCT patients are case reports. While case reports
provide important and detailed information at the patient level, often
detecting novelties and generating hypotheses, the lack of generaliz
ability, danger of over-interpretation, and publication bias are major
limitations of the case report genre [99]. For this reason, population
level inferences should be based on larger controlled experimental
studies. Second, into what extend hemoglobin genotype or sickle cell
therapy impact COVID-19 infection is largely unknown. Because of
marked differences in disease severity between different hemoglobin
genotypes, COVID-19 outcomes may vary between sickle cell patients,
which requires further investigation. Third, future studies should
include case-matched controls that account for the unique sample
characteristics of SCD and SCT populations. Patients with SCD and SCT
often have unique underlying conditions that could make them more
vulnerable to poor COVID-19 outcomes. Fourth, while most studies have
reported favorable short-term outcomes among COVID-19 patients with
SCD and SCT, especially related to severe illness and death, the longterm effects of SARS-CoV-2 infection are unknown. It is possible that
SCD patients with prior SARS-CoV-2 infection experience more lingering
symptoms and long-term health problems compared to survivors of
COVID-19 disease in the general population. Therefore, long term
follow-up studies with longitudinal assessment of post-COVID-19
symptoms are warranted.
Practice points

4.3. Hospitalization trends
Hospitalization rates for patients with SCT and COVID-19 varied
greatly between studies from 17.6% [33] to 61.1% [28], while 1 study
did not report it for their cohort [92]. In a large UK cohort, SCT was
associated with a 1.4-fold increased risk of hospitalization compared to
the general population adjusted for age, sex, and ethnicity [38]. Varia
tion in reported hospitalization rates is likely due to differences in cohort
characteristics as studies with higher hospitalization rates included
significantly older patients with SCT who had many comorbidities
[28,39], which can be viewed as additional risk factors for hospitaliza
tion. In fact, studies with comorbidities-matched controls showed no
differences in COVID-19-related hospitalization for those with SCT
compared to those without SCT [39,33], which implies that comorbid
ities and not SCT perse are associated with an increased risk of
admissions.
4.4. Mortality rate
Similar to hospitalization rates, the reported COVID-19-related
mortality rates for persons with SCT vary greatly between studies
from 2.2% [33] to 28.6% [92]. In one of the largest studies with SCT
patients to date, persons with SCT were found to have a 1.5-fold
increased risk of death due to COVID-19, similar to SCD albeit to a
lesser extend [38]. Another study confirmed these findings [92], but
only in a small sample without demographic-matched controls. There
are also large cohort studies that have shown no difference in mortality
rates between individuals with or without SCT and COVID-19
[39,33,93]. Differences in matching criteria, especially related to
comorbidity-matching, may explain some of the discrepancies observed
in reported mortality rates between studies. No studies analyzed risk
factors for mortality except for one [92], which found preexisting dia
betes to increase risk of death in SCT patients. Unique factors that lead to
severe disease and death among SCT patients, such as comorbidity
burden or genetic predisposition, are unknown and require further
investigation.

• Patients with SCD infected with SARS-CoV-2 should be followed very
closely as they often have underlying conditions that could make
them more vulnerable to poor COVID-19 outcomes.
• A low threshold for admission of SCD patients is common as SARSCoV-2 infection could trigger acute vaso-occlusive crisis requiring
hospitalization and due to overlap of SCD and COVID-19 symptoms
(e.g., the clinical picture for both ACS and COVID-19 pneumonia can
be similar).
• Transfusion and hydroxyurea treatment have demonstrated benefit
in treating SCD-related morbidity and mortality. The role of SCDdirected therapies in COVID-19 appears to be associated with
favorable outcomes and is under active investigation.
• While most SCD patients only experience mild to moderate COVID19 symptoms, similar to the general population, SCD is associated
with an increased risk of COVID-19-related hospitalization and
death, which indicates that serious illness and death still occurs
especially among vulnerable individuals in this patient group.
• Most COVID-19 patients with SCT appear not different from the
general population with COVID-19 in terms of admission laboratory
values, clinical course, hospitalization trends, and mortality, but
additional studies are needed to confirm these findings.

5. Summary and conclusions
This comprehensive review summarizes the clinical characteristics
and COVID-19-related outcomes of patients with SCD and SCT from the
published literature to date. While most studies reported mild to mod
erate COVID-19-related disease course in this patient population, the
literature suggests that SCD is associated with an increased risk of hos
pitalization and death from COVID-19, unless compared to controls with
similar comorbidities and end-organ damage. Advanced age, preexisting
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• Larger, multisite, randomized studies are needed to generate more
definite evidence related to COVID-19 outcomes among patients
with SCD/SCT.
• Because of marked differences in disease severity between different
hemoglobin genotypes, COVID-19 outcomes may vary between
sickle cell patients, which requires further investigation.
• Inclusion of properly matched controls is important to account for
the unique sample characteristics of SCD and SCT populations.
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the long-term effects of COVID-19 may affect these patients differ
ently as compared to the general population.
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